Release 5 R6 Ballot (3rd Draft)

This page is part of the FHIR Specification (v5.0.0: R5 - STU v6.0.0-ballot3: Release 6 Ballot (3rd Draft) (see Ballot Notes ). This is the The current published version in it's permanent home (it will always be available at this URL). is 5.0.0 . For a full list of available versions, see the Directory of published versions . Page versions: R5 R4B R4

Patient Care icon Work Group Maturity Level : 2   Trial Use Compartments : Group , Patient

Dependency Graph for Goal FMM level 2

Name Card. Type Dependency Analysis
. . Goal DomainResource
. . . identifier 0..* Identifier
. . . lifecycleStatus 1..1 code
. . . achievementStatus 0..1 CodeableConcept
. . . continuous 0..1 boolean
. . . priority 0..1 CodeableConcept
. . . description 1..1 CodeableConcept
. . . subject 1..1 Reference ( Patient | Group | Organization )
. . . start[x] 0..1
. . . . startDate date
. . . . startCodeableConcept CodeableConcept
... acceptance 0..* BackboneElement
.... participant 1..1 Reference ( Patient | Practitioner | RelatedPerson | PractitionerRole | CareTeam | Organization )
.... status 0..1 code
. . . . priority 0..1 CodeableConcept
. . . target 0..* BackboneElement
. . . . measure 0..1 CodeableConcept
. . . . detail[x] 0..1
. . . . . detailQuantity Quantity
. . . . . detailRange Range
. . . . . detailCodeableConcept CodeableConcept
. . . . . detailString string
. . . . . detailBoolean boolean
. . . . . detailInteger integer
. . . . . detailRatio Ratio
. . . . due[x] 0..1
. . . . . dueDate date
. . . . . dueDuration Duration
. . . statusDate 0..1 date
. . . statusReason 0..1 0..* string CodeableConcept
. . . source 0..1 Reference ( Patient | Practitioner | PractitionerRole | RelatedPerson | CareTeam | Group )
. . . addresses 0..* Reference ( Condition | Observation | MedicationStatement | MedicationRequest | NutritionOrder | ServiceRequest | RiskAssessment | Procedure | NutritionIntake )
. . . note 0..* Annotation outcome 0..* CodeableReference Type Error: (CodeableReference = FMM5-Draft vs. Element = FMM2-Trial Use)